Allogenetics employs genetic organ modification to create immunological invisibility of donor organs by permanently disabling HLA antigens, preventing recognition by the recipient's immune system. This approach eliminates the need for lifelong immunosuppression, enhancing graft survival and improving the quality of life for transplant recipients.
Funding
$7.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current organ transplantation methods require recipients to undergo lifelong immunosuppression, which compromises their immune system and overall quality of life. Existing approaches focus on suppressing the recipient's immune system rather than addressing the immunogenicity of the donor organ itself. This can lead to increased susceptibility to infections and other complications.
Solution
Allogenetics is developing a novel approach to organ transplantation by genetically modifying donor organs to make them immunologically invisible to the recipient's immune system. This is achieved by selectively and permanently disabling the HLA antigens on the donor organ cells, which are the primary targets of T cells and antibodies that cause rejection. By eliminating these targets, the recipient's immune system will no longer recognize the transplanted organ as foreign, preventing rejection without the need for continuous immunosuppression. The process involves ex vivo perfusion of the organ with viral transduction to modify the MHC genes, preventing their expression on the cell surface.
Target Audience
The primary target audience includes transplant centers, hospitals, and patients requiring organ transplantation, as well as researchers in the fields of transplant immunology and regenerative medicine.
Features
- Genetic modification of donor organs to eliminate HLA antigens expression.
- Viral transduction during ex vivo organ perfusion for efficient gene editing.
- Prevents immunological recognition of the organ as foreign.
- Eliminates the need for lifelong immunosuppression.
- Improves graft survival rates.
- Enhances the quality of life for transplant recipients.